1. Home
  2. ARIS vs MLYS Comparison

ARIS vs MLYS Comparison

Compare ARIS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARIS
  • MLYS
  • Stock Information
  • Founded
  • ARIS 2015
  • MLYS 2019
  • Country
  • ARIS United States
  • MLYS United States
  • Employees
  • ARIS N/A
  • MLYS N/A
  • Industry
  • ARIS Water Supply
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARIS Utilities
  • MLYS Health Care
  • Exchange
  • ARIS Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • ARIS 828.4M
  • MLYS 893.0M
  • IPO Year
  • ARIS 2021
  • MLYS 2023
  • Fundamental
  • Price
  • ARIS $21.83
  • MLYS $14.61
  • Analyst Decision
  • ARIS Buy
  • MLYS Strong Buy
  • Analyst Count
  • ARIS 6
  • MLYS 3
  • Target Price
  • ARIS $26.00
  • MLYS $33.00
  • AVG Volume (30 Days)
  • ARIS 697.9K
  • MLYS 679.3K
  • Earning Date
  • ARIS 05-06-2025
  • MLYS 05-12-2025
  • Dividend Yield
  • ARIS 2.69%
  • MLYS N/A
  • EPS Growth
  • ARIS 16.60
  • MLYS N/A
  • EPS
  • ARIS 0.83
  • MLYS N/A
  • Revenue
  • ARIS $452,529,000.00
  • MLYS N/A
  • Revenue This Year
  • ARIS $12.52
  • MLYS N/A
  • Revenue Next Year
  • ARIS $7.90
  • MLYS N/A
  • P/E Ratio
  • ARIS $25.13
  • MLYS N/A
  • Revenue Growth
  • ARIS 12.03
  • MLYS N/A
  • 52 Week Low
  • ARIS $13.34
  • MLYS $8.24
  • 52 Week High
  • ARIS $33.95
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • ARIS 35.94
  • MLYS 61.10
  • Support Level
  • ARIS $19.70
  • MLYS $14.03
  • Resistance Level
  • ARIS $26.75
  • MLYS $15.79
  • Average True Range (ATR)
  • ARIS 1.20
  • MLYS 0.93
  • MACD
  • ARIS -0.36
  • MLYS 0.16
  • Stochastic Oscillator
  • ARIS 22.06
  • MLYS 92.27

About ARIS Aris Water Solutions Inc.

Aris Water Solutions Inc is an environmental infrastructure and solutions company delivering full-cycle water handling and recycling solutions. Its integrated pipelines and related infrastructure create long-term value by delivering high-capacity, comprehensive produced water management, recycling, and supply solutions to operators in the core areas of the Permian Basin. The company manages its business through a single operating segment comprising two primary revenue streams, Produced Water Handling and Water Solutions. The Produced Water Handling business gathers, transports, and unless recycled, handles produced water generated from oil and natural gas production, and the Water Solutions business develops and operates recycling facilities to treat, store, and recycle produced water.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: